REVELATION BIOSCIENCES, INC.
REVB · XNASCIK 1810560fmd_0TGTRMZVCX0X5SRAQXTFQ8HFGYManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2019 to Sep 30, 2026, 28 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Research and development | – | – | 7 | 5 | 4 | 4 | 4 |
| Total operating expenses | – | 0 | 12 | 11 | 9 | 8 | 9 |
| Operating income | – | – | (12) | (11) | (9) | (8) | (9) |
| Interest expense | – | – | 0 | – | – | – | – |
| Interest and investment income | – | 0 | 0 | – | – | – | – |
| Other non-operating income (expense) | – | (1) | (0) | 0 | 9 | (7) | 0 |
| Income before taxes | – | (2) | – | – | – | – | – |
| Income tax expense | – | – | 0 | 0 | 0 | 0 | 0 |
| Net income | (0) | (2) | (12) | (11) | (0) | (15) | (9) |
| Net income to common shareholders | – | – | 0 | – | – | (15) | (15) |